Hovilpri (pritelivir)

Name: Hovilpri (pritelivir) in Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults: Disease description
Published: 2026-10-11T11:04:25-04:00

Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults

Also known as AIC316

Manufacturer: Asahi Kasei Therapeutics
Regulatory submission: NDA submitted February 2026 and approved October 2026
Launch: Anticipated before the end of 2026
Last updated: October 11, 2026

Section

Product information and disease description Place of product in therapy

Disease description

184 evidence topics · 78 sources

Definition and etiology25 evidence topics · 39 sources
Epidemiology55 evidence topics · 43 sources
Natural history, survival, and mortality25 evidence topics · 16 sources
Pathophysiology21 evidence topics · 29 sources
Diagnosis25 evidence topics · 29 sources
Clinical presentation - signs and symptoms12 evidence topics · 23 sources
Long-term morbidity6 evidence topics · 10 sources
Burden of Refractory mucocutaneous herpes simplex virus infection in immunocompromised adults15 evidence topics · 12 sources